These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31367835)

  • 1. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
    Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
    Viñal D; Gutierrez-Sainz L; Martinez D; Garcia-Cuesta JA; Pedregosa J; Villamayor J; Ostios L; Sanchez-Cabrero D; Higuera O; Pinto A; Rodriguez-Salas N; Espinosa E; de Castro J; Feliu J
    Clin Transl Oncol; 2021 Jun; 23(6):1185-1192. PubMed ID: 33226553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Hirasawa Y; Kubota Y; Mura E; Suzuki R; Tsurui T; Iriguchi N; Ishiguro T; Ohkuma R; Shimokawa M; Ariizumi H; Horiike A; Wada S; Ariyoshi T; Goto S; Otsuka K; Murakami M; Kiuchi Y; Yoshimura K; Hoffman RM; Tsunoda T
    Anticancer Res; 2024 Aug; 44(8):3397-3407. PubMed ID: 39060084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study.
    Kashimura S; Sato M; Inagaki T; Kin M; Manabe R; Kusumoto S; Horiike A; Tsunoda T; Kogo M
    Thorac Cancer; 2024 Oct; 15(28):2049-2060. PubMed ID: 39193939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
    Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Master VA; Ramalingam SS; Owonikoko TK; Harvey RD
    Cancer; 2019 Jan; 125(1):127-134. PubMed ID: 30329148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.
    Xie X; Liu J; Yang H; Chen H; Zhou S; Lin H; Liao Z; Ding Y; Ling L; Wang X
    Cancer Invest; 2019; 37(6):265-274. PubMed ID: 31304800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in older patients with metastatic cancer.
    Chen KH; Tsang NM; Chou WC; Tai SF; Liu SC; Lei KF; Chang KP; Chuang WC; Pai PC
    J Geriatr Oncol; 2019 Sep; 10(5):757-762. PubMed ID: 31085137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragalus Polysaccharide Injection (PG2) Normalizes the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Lung Cancer Receiving Immunotherapy.
    Tsao SM; Wu TC; Chen J; Chang F; Tsao T
    Integr Cancer Ther; 2021; 20():1534735421995256. PubMed ID: 33583212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
    Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
    Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.